INTRODUCTION
============

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, and is estimated to be the cause of approximately 25% of chronic liver disease cases.[@b1-gnl-13-658],[@b2-gnl-13-658] NAFLD comprises a spectrum of pathological conditions, which range from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. NAFLD, especially NASH, can progress to advanced liver disease, leading to cirrhosis, liver failure, and hepatocellular carcinoma[@b3-gnl-13-658]--[@b5-gnl-13-658] and is now a major cause of liver-related morbidity and mortality.[@b6-gnl-13-658]

Although NAFLD comprises histological changes in the liver, its clinical burden is not confined to liver-related morbidity and mortality. NAFLD is now regarded as a multisystem disease associated with extrahepatic chronic diseases, such as diabetes, cardiovascular disease (CVD), and metabolic syndrome. Previous studies have reported that NAFLD is associated with subclinical atherosclerosis, such as coronary artery calcification[@b7-gnl-13-658],[@b8-gnl-13-658] and carotid intima-media thickness (CIMT).[@b9-gnl-13-658] Moreover, in the natural course of NAFLD, the most important cause of death is CVD.[@b3-gnl-13-658],[@b10-gnl-13-658] In previous studies, mortality from CVD in NAFLD patients has been shown to be associated with advanced fibrosis.[@b3-gnl-13-658] Thus, identifying patients with advanced fibrosis among subjects with NAFLD is important in identifying those with a high risk of developing CVD.

Liver biopsy is considered a reference method for assessing the severity of inflammation and degree of fibrosis in NAFLD patients. However, liver biopsy is an invasive procedure that is associated with several complications, and the sampling error and inter- and intra-observer variability can be major issues. Because of these limitations, noninvasive methods to assess the severity of hepatic fibrosis were developed using serum markers. Many serum biomarkers were developed and include combinations of direct markers that reflect extracellular matrix turnover and indirect markers that can be detected by simple biochemical tests.[@b11-gnl-13-658]--[@b13-gnl-13-658] These biomarkers were validated in subjects with NAFLD in many studies and are now included in clinical practice guidelines to define the presence of advanced fibrosis.[@b12-gnl-13-658],[@b13-gnl-13-658]

Therefore, in this cross-sectional study, we aimed to assess the association between noninvasive serum fibrosis markers and the coronary artery calcium score (CACS), which is a strong predictor of cardiovascular events, in subjects with NAFLD, as detected by ultrasonography.

MATERIALS AND METHODS
=====================

1. Study population
-------------------

We conducted a retrospective, cross-sectional study on 34,890 asymptomatic subjects who received an abdominal ultrasound (US) as a health check-up at the Health Promotion Center of St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, between January 2011 and December 2015. Subjects without evidence of fatty liver on US (n=18,471) and those who did not undergo a coronary computed tomography (CT) scan (n=15,501) were excluded. Coronary CT scan was performed on the subjects who wanted the test. Only data from the first check-up were included for subjects who underwent a health check-up more than twice (n=48). We excluded subjects who met any of the following criteria: (1) average alcohol consumption ≥30 g/day in men and ≥20 g/day in women (n=126); (2) hepatitis B surface antigen positive or undetermined hepatitis B surface antigen (n=17); (3) hepatitis C antibody positive (n=8); (4) lack of laboratory data (n=28); and (5) previous history of heart disease (n=26). Finally, we analyzed 665 subjects in this study ([Fig. 1](#f1-gnl-13-658){ref-type="fig"}).

The study was approved by the Institutional Review Board of St. Vincent's Hospital (VC17RESI0234).

2. Abdominal US
---------------

Abdominal US was performed using an ACUSON Sequoia 512 (Siemens Medical Solution, Mountain View, CA, USA) or EPIQ 5 (Philips Ultrasound, Bothell, WA, USA) by experienced radiologists at the Health Promotion Center of St. Vincent's Hospital. US examiners were blinded to the subjects' health status. Hepatic steatosis was diagnosed by the following criteria: (1) parenchymal brightness; (2) liver to kidney contrast; (3) deep beam attenuation; and (4) vessel blurring.

3. Coronary CT imaging
----------------------

Coronary CT imaging was conducted using a 128-multislice scanner (Optima CT660; GE Healthcare Japan Corp., Tokyo, Japan) or dual source CT system (SOMATOM Definition Flash; Siemens Healthcare, Forchheim, Germany) with administration of 90 to 100 mL of iodinated contrast medium (Ultravist^®^ 370; Bayer Healthcare, Berlin, Germany). Images were reconstructed at a 3-mm slice thickness. CACS was calculated as described by Agatston *et al*.[@b14-gnl-13-658] using the AW server 4.6 (GE Healthcare). In brief, calcium deposits with an attenuation of more than 130 Hounsfield units (HU) are multiplied by a density weighting factor derived from the maximal CT attenuation within a given calcified lesion. The score for all lesions in all coronary arteries is then summed.

4. Clinical and laboratory data
-------------------------------

The participants' demographic data and medical history, such as hypertension, diabetes, CVD, alcohol consumption, smoking status, and medication use, were obtained through a self-administered health questionnaire. The cutoff value of increased age was 55, which is a coronary artery disease (CAD) risk factor in women.[@b15-gnl-13-658] Smoking status was categorized into two groups: current smokers and nonsmokers or past-smokers. Current smokers were defined as those who smoked at least one cigarette per day during the past 1 year. The participants were asked about their average frequency and amount of alcohol consumption for 1 year. The average amount of alcohol consumption per day was calculated, and men who consumed more than 30 g/day and women who consumed more than 20 g/day were excluded. Anthropometric measurements of the subjects were performed by trained nurses. Body weight and height were measured using a digital scale, and body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. The waist circumference was measured at the level of the midpoint between the iliac crest and costal margin. Subjects with a systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or history of antihypertensive drug use were defined as having hypertension. Subjects with a fasting serum glucose level ≥126 mg/dL or history of hypoglycemic agent use were defined as having diabetes mellitus. Laboratory data included albumin, bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, glucose, creatinine, platelet count, hepatitis B surface antigen, and antibody to hepatitis C virus.

The estimated glomerular filtration rate (eGFR) was calculated by the Modification of Diet in Renal Disease equation as follows: 175×serum creatinine (mg/dL)^−1.154^×age (year)^−0.203^×0.723 (if female)×1.212 (if African American).[@b16-gnl-13-658]

5. Noninvasive steatosis and fibrosis markers
---------------------------------------------

To assess the association between hepatic steatosis or fibrosis and CACS, we calculated the hepatic steatosis index (HSI)[@b17-gnl-13-658] and fatty liver index (FLI)[@b18-gnl-13-658] as indexes of hepatic steatosis and NAFLD fibrosis score (NFS),[@b19-gnl-13-658] Fibrosis-4 (FIB-4) score,[@b20-gnl-13-658] Forn's index,[@b21-gnl-13-658] and AST to platelet ratio index (APRI)[@b22-gnl-13-658] as indexes of liver fibrosis. The HSI was calculated as 8×ALT/AST+BMI (+ 2 if type 2 diabetes, + 2 if female) and FLI was calculated as e^y^/(1+e^y^)×100, where y=0.953×ln(triglycerides, mg/dL)+0.139×(BMI, kg/m^2^)+0.718×ln (GGT, U/L)+0.053×(waist circumference, cm)--15.745. The NFS was calculated as −1.675+0.037×(age, year)+0.094×(BMI, kg/m^2^)+1.13×impaired fasting glucose/diabetes (yes=1, no=0)+0.99×AST/ALT ratio−0.013×(platelet count, ×10^9^/L)−0.66×(albumin, g/dL). The FIB-4 score was calculated as (age×AST)/(platelet count×\[square root of ALT\]). Forn's index was calculated by applying the following regression equation: 7.811--3.131×ln (platelet count, 10^9^/L) + 0.781×ln (GGT, IU/L) + 3.467×ln(age, year)−0.014×(cholesterol, mg/dL). The APRI was calculated based on the following formula: AST (IU/L)/AST upper limit of normal (IU/L)/platelet count in (10^9^/L)×100.

6. Statistical analysis
-----------------------

The data were expressed according to the properties of the variables. Continuous variables are presented as the means and standard deviations. Categorical variables are presented as frequencies and percentages. All subjects were categorized into three groups: CACS=0, \>0--100, and over 100. Categorical variables were compared using the chi-square test or Fisher exact test, and continuous variables were compared using one-way analysis of variance with Scheffe *post hoc* test. The association between clinical characteristics and increased CACS was evaluated using multinomial logistic regression analysis. In addition, to identify the risk factors for CACS \>100, univariate and multivariate binary logistic regression analyses were performed using the backward elimination method (likelihood ratio). In multivariate analysis, statistically significant factors (p\<0.05) and factors with near-marginal significance (p\<0.10) were included. Because the noninvasive fibrosis scores included age, which is a significant risk factor, multi-collinearity could be present. Therefore, we performed multivariate analysis while excluding these scores. The accuracy in predicting CACS \>100 was assessed by the area under the receiver operating characteristics (AUROC) curve. The AUROC curve was performed to calculate the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The cutoff point that maximized the Youden's index (J=sensitivity+specificity−1) was chosen. Noninvasive steatosis and fibrosis scores were adjusted by age and gender (model 1) and adjusted by significant risk factors by multivariate analysis (model 2) using binary logistic regression analysis. A p-value less than 0.05 was considered to be statistically significant. Statistical analysis was performed using SPSS version 21.0 (IBM Corp., Armonk, NY, USA).

RESULTS
=======

1. Baseline characteristics
---------------------------

The baseline characteristics of the participants are shown in [Table 1](#t1-gnl-13-658){ref-type="table"}. The mean age of all subjects was 51.5±9.3 years, and 486 subjects (73.5%) were male. The prevalence rates of hypertension, diabetes, and metabolic syndrome were 43.5%, 14.1%, and 51.7%, respectively. Most subjects (n=485, 72.9%) had no calcification in their coronary arteries (CACS=0), whereas 128 subjects (19.2%) had a CACS between 0 and 100, and 52 subjects (7.8%) had a CACS over 100. As the CACS increased, age, BMI, waist circumference, serum fasting glucose level, and serum creatinine increased (all p\<0.05). The prevalence of diabetes, hypertension and metabolic syndrome increased (all p\<0.01). Moreover, noninvasive fibrosis markers, such as the NFS and the FIB-4 score and Forn's index, significantly increased as the CACS increased (all p\<0.001). CACS also had significant positive correlation with the NFS (r=0.157, p\<0.001), and the FIB-4 score (r=0.152, p\<0.001), and Forn's index (r=0.120, p=0.002) ([Supplementary Table 1](#s1-gnl-13-658){ref-type="supplementary-material"}).

2. Factors associated with CACS \>100
-------------------------------------

The results from multinomial regression logistic regression models that explored risk factor relationships with CACS \>0--100 and CACS\>100 are displayed in [Table 2](#t2-gnl-13-658){ref-type="table"}. At \>55 years of age, the presence of hypertension and diabetes, elevated fasting plasma glucose, serum bilirubin level and triglyceride level were significant factors associated with CACS 0--100. At \>55 years of age, the presence of hypertension and diabetes, BMI ≥25 kg/m^2^, elevated fasting plasma glucose and decreased eGFR were significant factors associated with CACS \>100. Noninvasive fibrosis markers were significantly associated with CACS, except for the APRI for CACS 0--100. However, noninvasive steatosis markers were not associated with CACS, except for the FLI for CACS \>100.

Univariate binary logistic regression analysis identified three significant factors and two factors with marginal significance associated with CACS \>100 ([Table 3](#t3-gnl-13-658){ref-type="table"}). At \>55 years of age, the presence of diabetes mellitus and eGFR (all p\<0.05) were statistically significant factors, and the presence of hypertension and BMI ≥25 kg/m^2^ were factors with marginal significance associated with CACS \>100 (p=0.065 and p=0.065). Multivariate binary logistic regression analysis that included these factors revealed that older age, elevated BMI and decreased eGFR were significant factors for predicting CACS \>100 (p\<0.001, p=0.016, and p=0.028, respectively) ([Table 3](#t3-gnl-13-658){ref-type="table"}).

To assess the association between noninvasive steatosis and fibrosis markers and CACS \>100, we performed multivariate analysis adjusted for potential confounders ([Table 4](#t4-gnl-13-658){ref-type="table"}). In model 1, which was adjusted for age and gender, the NFS and the FIB-4 score and APRI were significant predictive factors for CACS \>100. In model 2, which was adjusted for age, gender, BMI and eGFR, the NFS and the FIB-4 score and APRI were also significant predictive factors for CACS \>100. Unlike noninvasive fibrosis markers, noninvasive steatosis markers were not significant factors for CACS \>100 except FLI in model 1.

3. Performance of noninvasive fibrosis markers in predicting coronary artery calcification
------------------------------------------------------------------------------------------

The performance of the noninvasive fibrosis markers in predicting CACS \>100 in the subjects with NAFLD was evaluated by ROC curves ([Fig. 2](#f2-gnl-13-658){ref-type="fig"}). [Table 4](#t4-gnl-13-658){ref-type="table"} shows the AUROC for noninvasive fibrosis markers in predicting CACS \>100. The AUROCs for the NFS and the FIB-4 score, Forn's index and APRI were 0.689, 0.683, 0.659, and 0.595, respectively. There were no significant differences among the AUROCs, except between the NFS and APRI (p=0.028) and between the FIB-4 score and APRI (p=0.008). The best performance levels for the NFS and the FIB-4 score, Forn's index, and APRIs were observed at cutoff values of −2.745, 0.85, 3.8 and 0.219, respectively. These cutoff values exhibited sensitivity and specificity values of 92.3% and 37.2% for the NFS, 82.7% and 50.4% for the FIB-4 score, 80.8% and 43.7% for Forn's index, and 75.0% and 47.6% for the APRI, respectively.

Because the performance of original noninvasive fibrosis markers was less predictive, new prognostic models, integrating the noninvasive fibrosis markers and the risk factors for CAD (older age, gender, elevated BMI and decreased eGFR), were developed based on the results obtained from the multivariable logistic regression model ([Supplementary Table 2](#s1-gnl-13-658){ref-type="supplementary-material"}).

The AUROCs for the NFS model, the FIB-4 score model, Forn's index model and APRI model were increased to 0.797, 0.785, 0.775, and 0.782, respectively. The best performance levels for the NFS model, the FIB-4 score model, Forn's index model, and APRI model were observed at cutoff values of −2.459, −2.442, −2.441, and −2.231, respectively. These cutoff values exhibited sensitivity and specificity values of 86.5% and 65.4% for the NFS model, 80.8% and 66.2% for the FIB-4 score model, 69.2% and 75.0% for Forn's index model, and 65.4% and 78.8% for the APRI model, respectively ([Table 5](#t5-gnl-13-658){ref-type="table"}).

Because age was the most significant predictive factor, we analyzed the predictive power of noninvasive fibrosis markers for CACS \>100 ([Table 6](#t6-gnl-13-658){ref-type="table"}). The NFS and the FIB-4 score, and APRI were significant factors in the older age group, but not in the younger age group.

DISCUSSION
==========

In this study, we found that noninvasive fibrosis markers, such as the NFS and the FIB-4 score and Forn's index scores, significantly increased as the CACS increased. Noninvasive fibrosis markers were independently associated with CACS \>100. Moreover, new scores integrating noninvasive fibrosis markers and risk factors for CAD showed good discriminatory power in predicting CACS \>100.

Previous cross-sectional studies and meta-analyses showed that NAFLD was associated with subclinical atherosclerosis, independent of traditional CVD risk factors.[@b23-gnl-13-658],[@b24-gnl-13-658] NAFLD is also associated with the progression of subclinical atherosclerosis markers, such as CIMT and CAC.[@b25-gnl-13-658],[@b26-gnl-13-658] The CACS measured by cardiac CT represents the atherosclerotic burden of coronary artery. In addition, the CACS is associated with future cardiovascular events in several studies.[@b24-gnl-13-658],[@b27-gnl-13-658],[@b28-gnl-13-658] In our study, subjects with a high CACS tended to have more metabolic syndrome features, such as hypertension, diabetes, high BMI, and high waist circumference ([Table 1](#t1-gnl-13-658){ref-type="table"}), and old age, elevated BMI and decreased eGFR were significantly associated with a high CACS after adjusting for these metabolic features ([Table 3](#t3-gnl-13-658){ref-type="table"}). These results are expected, considering that variables related to metabolic syndrome, renal disease and age are well-established risk factors for CVD.[@b29-gnl-13-658],[@b30-gnl-13-658] In addition to these well-established risk factors, noninvasive fibrosis markers were also significantly associated with a high CACS in our study. Our results suggest that the risk of CAD increases as hepatic fibrosis progresses in subjects with NAFLD. This finding is consistent with data from You *et al*.[@b31-gnl-13-658] who showed that the liver stiffness value measured by transient elastography (TE) is associated with a higher CACS in subjects with NAFLD. Our study also showed that noninvasive fibrosis markers combined with risk factors for CAD showed good performance in predicting a high CACS (\>100), which is associated with future CVD ([Fig. 2](#f2-gnl-13-658){ref-type="fig"}). Therefore, noninvasive fibrosis markers could be useful tools for identifying subjects with a high risk for CVD development.

Previous studies have reported that CVD is a major cause of death among subjects with NAFLD, and the presence and stage of hepatic fibrosis are the main determinants of mortality from CVD or liver-related disease.[@b3-gnl-13-658],[@b5-gnl-13-658],[@b10-gnl-13-658],[@b32-gnl-13-658] Although liver biopsy remains the gold standard for assessing the fibrosis stage in patients with NAFLD, thus far, it is impractical for widespread use given the high prevalence of NAFLD. Noninvasive methods to assess hepatic fibrosis include imaging techniques and serum biomarkers. The most validated imaging modality in patients with NAFLD is TE, which showed high performance for advanced fibrosis (stage 3 or 4) (sensitivity 85%--92%, specificity 82%--92%).[@b12-gnl-13-658],[@b33-gnl-13-658],[@b34-gnl-13-658] However, TE could be limited in obese patients due to measurement failure or unreliable results, although the use of the XL probe improved these limitations.[@b35-gnl-13-658]--[@b37-gnl-13-658] In addition, there were conflicting data regarding the effect of hepatic steatosis on the liver stiffness value of TE.[@b38-gnl-13-658],[@b39-gnl-13-658] Magnetic resonance elastography (MRE) analyzes almost the entire liver and has good applicability in patients with obesity. Some studies have reported that MRE is more accurate than TE for the diagnosis of advanced fibrosis.[@b40-gnl-13-658]--[@b42-gnl-13-658] However, MRE is too costly and time-consuming and therefore is not suitable for routine screening of NAFLD patients in clinical practice. On the other hand, serum biomarkers have the advantages of low cost, high applicability (\>95%), and widespread availability.[@b12-gnl-13-658] In addition, serum biomarkers, such as the NFS and FIB-4 score, have been well-validated in subjects with NAFLD, which shows that these markers have good performance in diagnosing advanced fibrosis.[@b43-gnl-13-658] Therefore, serum biomarkers are an adequate modality that can be easily used to identify patients with advanced fibrosis in routine clinical practice.

NAFLD is associated with increased risk of chronic kidney disease (CKD), and metabolic status in NAFLD patients impacts on CKD development.[@b44-gnl-13-658],[@b45-gnl-13-658] Coronary artery calcification is highly prevalent and more severe in patients with CKD.[@b46-gnl-13-658] In addition, CKD is strongly associated with development of CVD.[@b47-gnl-13-658] In CKD patients, coronary artery calcification is associated with systemic inflammation.[@b48-gnl-13-658] In the same manner, CAD in NAFLD patients is also associated with systemic inflammation.[@b49-gnl-13-658] Therefore, it is natural that decreased eGFR was a significant factor for predicting CACS \>100, consistent with a previous study.[@b31-gnl-13-658]

Our study has some limitations. First, the cross-sectional design makes it difficult to determine the causal relationships between noninvasive fibrosis markers and coronary artery calcifications. Second, the absence of a liver biopsy as a reference standard for the diagnosis of fatty liver and degree of liver fibrosis could be a limitation. We diagnosed NAFLD by ultrasonography, which has difficulty in identifying fatty infiltration below 30%, and the intra- and inter-observer variability can affect the diagnosis.[@b50-gnl-13-658] However, ultrasonography has the advantages of safety, relatively low cost, repeatability, high sensitivity and specificity.[@b51-gnl-13-658] Given these strengths, ultrasonography could be a good imaging technique for diagnosing NAFLD in the general population. In addition, although there could be discordance between noninvasive markers and liver biopsy, NFS and FIB-4 score are more adequate than liver biopsy in clinical practice due to the low prevalence of significant fibrosis, as shown in our study. Third, selection bias could have been involved because subjects with high CVD risk are more likely to have a coronary CT scan in a health check-up. Indeed, included subjects were older and had higher noninvasive fibrosis markers ([Supplementary Table 3](#s1-gnl-13-658){ref-type="supplementary-material"}). However, noninvasive fibrosis markers were independently associated with high CACS after adjusting for other risk factors. Fourth, while original noninvasive fibrosis markers and new models integrating noninvasive fibrosis markers and risk factors for CAD showed high sensitivity and NPV for predicting high CACS, their specificity and PPV were too low. This result might be caused by low prevalence of high CACS (7.8%). Fifth, because we investigated some data using a self-reporting questionnaire, we should consider the possibility of a response bias. In addition, data investigation by questionnaire makes it difficult to identify subjects who are taking drugs that could affect hepatic fibrosis and coronary calcification, such as an angiotensin II receptor antagonist or statin.[@b52-gnl-13-658],[@b53-gnl-13-658] Therefore, prospective studies are necessary to investigate the causal relationship and eliminate the effect of confounding factors between hepatic fibrosis and coronary subclinical atherosclerosis in subjects with NAFLD. In addition, the cutoff values of noninvasive fibrosis markers and new models to discriminate patients with risk of CAD should be validated in further studies.

In conclusion, high noninvasive fibrosis markers are significantly associated with a high CACS in subjects with NAFLD. Moreover, new models integrating noninvasive markers and the risk factors for CAD showed good discriminatory power for predicting CACS \>100. Therefore, noninvasive fibrosis markers and risk factors for CAD may be useful tools for identifying NAFLD subjects with a high risk of future CVD development.
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###### 

Baseline Characteristics

  Characteristic                    Total (n=665)   Coronary artery calcium score   p-value                                                                                                                                                        
  --------------------------------- --------------- ------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------
  Age, yr                           51.5±9.3        49.7±8.7                        55.2±9.5[\*](#tfn3-gnl-13-658){ref-type="table-fn"}       58.7±7.6[\*](#tfn3-gnl-13-658){ref-type="table-fn"}                                                  \< 0.001
  Male sex                          486 (73.5)      348 (71.8)                      98 (76.6)                                                 43 (82.7)                                                                                            0.162
  Smoking                           174 (26.2)      127 (26.2)                      36 (28.1)                                                 11 (21.2)                                                                                            0.628
  Diabetes mellitus                 94 (14.1)       54 (11.1)                       27 (21.1)[\*](#tfn3-gnl-13-658){ref-type="table-fn"}      13 (25.0)[\*](#tfn3-gnl-13-658){ref-type="table-fn"}                                                 0.001
  Hypertension                      289 (43.5)      190 (39.2)                      70 (54.7)[\*](#tfn3-gnl-13-658){ref-type="table-fn"}      29 (55.8)[\*](#tfn3-gnl-13-658){ref-type="table-fn"}                                                 0.001
  Lipid lowering medication         38 (5.7)        21 (4.3)                        12 (9.4)[\*](#tfn3-gnl-13-658){ref-type="table-fn"}       5 (9.6)                                                                                              0.041
  Systolic blood pressure, mm Hg    128.6±13.8      127.8±13.7                      131.7±14.3[\*](#tfn3-gnl-13-658){ref-type="table-fn"}     129.2±11.7                                                                                           0.016
  Diastolic blood pressure, mm Hg   77.8±9.9        77.8±10.1                       78.7±9.1                                                  75.3±9.4                                                                                             0.115
  Body mass index, kg/m^2^          25.9±3.0        25.7±2.9                        26.4±3.1                                                  26.4±2.7                                                                                             0.037
  Waist circumference, cm           89.1±8.1        88.7±8.2                        90.2±7.7                                                  91.1±7.0                                                                                             0.031
  Metabolic syndrome                344 (51.7)      231 (47.6)                      80 (62.5)[\*](#tfn3-gnl-13-658){ref-type="table-fn"}      33 (63.5)[\*](#tfn3-gnl-13-658){ref-type="table-fn"}                                                 0.002
  Albumin, g/dL                     4.5±0.3         4.55±0.26                       4.53±0.25                                                 4.54±0.28                                                                                            0.637
  Bilirubin, mg/dL                  0.95±0.39       0.97±0.39                       0.89±0.36                                                 0.97±0.43                                                                                            0.134
  AST, IU/L                         23.2±9.9        23.2±10.0                       23.2±10.1                                                 23.6±8.5                                                                                             0.97
  ALT, IU/L                         31.2±22.2       31.4±21.4                       31.7±25.8                                                 29.0±19.8                                                                                            0.737
  GGT, IU/L                         40.7±38.0       40.6±35.8                       40.1±37.6                                                 43.3±55.9                                                                                            0.869
  Total cholesterol, mg/dL          205.8±38.9      205.2±37.7                      206.7±41.6                                                209.0±43.6                                                                                           0.759
  Triglyceride, mg/dL               151.2±86.5      148.8±91.0                      158.7±70.2                                                155.1±79.4                                                                                           0.485
  HDL cholesterol, mg/dL            43.6±10.2       43.8±10.1                       42.1±9.6                                                  45.0±11.7                                                                                            0.131
  LDL cholesterol, mg/dL            127.9±33.8      128.0± 32.6                     129.5±37.3                                                123.6±36.4                                                                                           0.571
  Fasting glucose, mg/dL            102.7±25.0      100.3±23.4                      108.3±28.0[\*](#tfn3-gnl-13-658){ref-type="table-fn"}     110.9±28.2                                                                                           \<0.001
  Creatinine, mg/dL                 0.9±0.2         0.87±0.17                       0.90±0.22                                                 0.92±0.20                                                                                            0.029
  Platelet, 10^3^/mm^3^             250.0±53.2      251.8±53.1                      248.5±54.0                                                237.2±50.5                                                                                           0.162
  Alcohol consumption, g/day        7.6±8.4         7.8±8.5                         6.2±7.8                                                   8.8±8.4                                                                                              0.084
  NAFLD fibrosis score              −2.266±1.120    −2.428±1.078                    −1.955±1.105[\*](#tfn3-gnl-13-658){ref-type="table-fn"}   −1.516±1.094[\*](#tfn3-gnl-13-658){ref-type="table-fn"},[†](#tfn4-gnl-13-658){ref-type="table-fn"}   \<0.001
  FIB-4 score                       0.95±0.45       0.90±0.38                       1.02±0.43[\*](#tfn3-gnl-13-658){ref-type="table-fn"}      1.26±0.83[\*](#tfn3-gnl-13-658){ref-type="table-fn"},[†](#tfn4-gnl-13-658){ref-type="table-fn"}      \<0.001
  Forn's index                      4.00±1.21       3.86±1.16                       4.26±1.29[\*](#tfn3-gnl-13-658){ref-type="table-fn"}      4.64±1.18[\*](#tfn3-gnl-13-658){ref-type="table-fn"}                                                 \<0.001
  APRI                              0.26±0.14       0.26±0.15                       0.26±0.14                                                 0.27±0.10                                                                                            0.791

Data are presented as mean±SD or number (%).

AST, aspartate transaminase; ALT, alanine transaminase; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4; APRI, AST to platelet ratio index.

p\<0.05 vs CACS=0;

p\<0.05 vs CACS \>0--100.

###### 

Factors Associated with Coronary Artery Calcium Score According to the Multinomial Logistic Regression Model in Nonalcoholic Fatty Liver Disease Patients

  Variable                                       CACS (\>0--100)        CACS (\>100)                           
  ---------------------------------------------- ---------------------- -------------- ----------------------- ---------
  Age \>55 yr                                    2.069 (1.390--3.080)   \<0.001        5.784 (3.078--10.867)   \<0.001
  Male sex                                       1.286 (0.817--2.025)   0.278          1.881 (0.893--3.963)    0.097
  Hypertension                                   1.874 (1.265--2.776)   0.002          1.958 (1.100--3.485)    0.022
  Diabetes                                       2.134 (1.281--3.554)   0.004          2.660 (1.336--5.296)    0.005
  Smoking                                        1.103 (0.714--1.705)   0.659          0.756 (0.377--1.516)    0.756
  BMI ≥25 kg/m^2^                                1.273 (0.853--1.899)   0.238          1.884 (1.007--3.523)    0.048
  WC ≥90 cm (male) or ≥80 cm (female)            1.274 (0.856--1.896)   0.233          1.681 (0.917--3.083)    0.093
  Albumin \<4.5 g/dL                             0.874 (0.591--1.292)   0.500          1.231 (0.694--2.184)    0.478
  Bilirubin \>1.0 mg/dL                          0.599 (0.382--0.940)   0.026          0.951 (0.517--1.748)    0.871
  eGFR \<90 mL/min/1.73 m^2^                     1.395 (0.934--2.085)   0.104          2.699 (1.382--5.272)    0.004
  LDL ≥130 mg/dL                                 1.030 (0.697--1.522)   0.882          0.638 (0.350--1.160)    0.638
  TG ≥150 mg/dL                                  1.653 (1.116--2.449)   0.012          1.453 (0.819--2.579)    0.202
  HDL \<40 mg/dL (male) or \<50 mg/dL (female)   1.282 (0.867--1.896)   0.213          1.029 (0.581--1.824)    0.921
  Noninvasive steatosis marker                                                                                 
   Hepatic steatosis index                       0.999 (0.951--1.049)   0.999          0.939 (0.872--1.011)    0.094
   Fatty liver index                             1.009 (0.998--1.020)   0.100          1.019 (1.004--1.035)    0.015
  Noninvasive fibrosis marker                                                                                  
   NAFLD fibrosis score (\> −2.745)              1.675 (1.094--2.564)   0.018          7.863 (2.790--22.161)   \<0.001
   FIB-4 (\>0.85)                                1.788 (1.202--2.660)   0.004          5.475 (2.612--11.479)   \<0.001
   Forn's index (\>3.8)                          1.711 (1.138--2.572)   0.01           3.635 (1.783--7.410)    \<0.001
   APRI (\>0.219)                                1.219 (0.823--1.803)   0.323          2.843 (1.481--5.460)    0.002

Reference category: CACS=0

CACS, coronary artery calcium score; OR, odds ratio; CI, confidential interval; BMI, body mass index; WC, waist circumference; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; TG, triglyceride; HDL, high-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index.

###### 

Factors Associated with a Coronary Calcium Score \>100 in Subjects with Nonalcoholic Fatty Liver Disease

  Variable                                       Univariate              Multivariate                          
  ---------------------------------------------- ----------------------- -------------- ---------------------- ---------
  Age \>55 yr                                    4.909 (2.633--9.153)    \<0.001        4.809 (2.556--9.049)   \<0.001
  Male sex                                       1.789 (0.853--3.750)    0.123                                 
  Hypertension                                   1.712 (0.968--3.028)    0.065                                 
  Diabetes                                       2.189 (1.120--4.278)    0.022                                 
  Smoking                                        0.741 (0.372--1.476)    0.393                                 
  BMI ≥25 kg/m^2^                                1.055 (0.962--1.157)    0.065          2.072 (1.093--3.928)   0.026
  WC ≥90 cm (male) or ≥80 cm (female)            1.599 (0.877--2.917)    0.126                                 
  Albumin, g/dL                                  0.914 (0.304--2.748)    0.873                                 
  Bilirubin, mg/dL                               1.127 (0.555--2.289)    0.74                                  
  eGFR \<90 mL/min/1.73 m^2^                     2.521 (1.297--4.901)    0.006          2.149 (1.088--4.245)   0.028
  Cholesterol, mg/dL                             1.002 (0.995--1.010)    0.531                                 
  LDL, mg/dL                                     0.996 (0.987--1.004)    0.339                                 
  TG ≥150 mg/dL                                  1.308 (0.741--2.308)    0.354                                 
  HDL \<40 mg/dL (male) or \<50 mg/dL (female)   0.977 (0.555--1.722)    0.937                                 
  Noninvasive steatosis marker                                                                                 
   Hepatic steatosis index                       0.991 (0.939--1.047)    0.750                                 
   Fatty liver index                             1.008 (0.997--1.020)    0.155                                 
  Noninvasive fibrosis marker                                                                                  
   NAFLD fibrosis score                          1.943 (1.488--2.537)    \<0.001                               
   FIB-4                                         3.018 (1.759--5.177)    \<0.001                               
   Forn's index                                  1.605 (1.269--2.030)    \<0.001                               
   APRI                                          1.804 (0.321--10.124)   0.503                                 

OR, odds ratio; CI, confidential interval; BMI, body mass index; WC, waist circumference; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; TG, triglyceride; HDL, high-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index.

###### 

Associations between Noninvasive Serum Fibrosis Markers and a Coronary Calcium Score \>100 in Subjects with Nonalcoholic Fatty Liver Disease

                                     Model 1                 Model 2                          
  ---------------------------------- ----------------------- --------- ---------------------- -------
  NAFLD fibrosis score (\> −2.745)   4.375 (1.511--12.663)   0.006     3.91 (1.339--11.416)   0.013
  FIB-4 score (\>0.85)               2.791 (1.248--6.243)    0.012     2.573 (1.147--5.769)   0.022
  Forn's index (\>3.8)               1.539 (0.698--3.396)    0.285     1.536 (0.698--3.383)   0.286
  APRI (\>0.219)                     2.365 (1.212--4.615)    0.012     2.151 (1.093--4.231)   0.027
  Hepatic steatosis index            1.017 (0.959--1.077)    0.578     0.99 (0.920--1.065)    0.783
  Fatty liver index                  1.013 (1.000--1.027)    0.049     1.009 (0.994--1.026)   0.243

Model 1: adjusted for age (≥55 years of age) and gender. Model 2: adjusted for age (≥55 years of age), gender, BMI (≥25 kg/m^2^), and eGFR\<90 mL/min/1.73 m^2^.

OR, odds ratio; CI, confidential interval; NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4; APRI, aspartate transaminase to platelet ratio index; BMI, body mass index; eGFR, estimated glomerular filtration rate.

###### 

Performance of Noninvasive Fibrosis Markers in Predicting a Coronary Calcium Score \>100 Using the Optimal Cutoff Point

  Variable                      AUROC   Cutoff value   Sensitivity, %   Specificity, %   PPV, %   NPV, %
  ----------------------------- ------- -------------- ---------------- ---------------- -------- --------
  Original score                                                                                  
   NAFLD fibrosis score         0.689   −2.745         92.3             37.2             11.1     98.3
   FIB-4                        0.683   0.85           82.7             50.4             12.4     97.2
   Forn's index                 0.659   3.8            80.8             43.7             10.9     96.4
   APRI                         0.595   0.219          75.0             47.6             10.8     95.7
  New model                                                                                       
   NAFLD fibrosis score model   0.797   −2.459         86.5             65.4             17.5     98.3
   FIB-4 score model            0.785   −2.442         80.8             66.2             16.9     97.6
   Forn's index model           0.775   −2.441         69.2             75.0             19.0     96.6
   APRI model                   0.782   −2.231         65.4             78.8             20.7     96.4

AUROC, area under receiver operating characteristic curve; PPV, positive predictive value; NPV, negative predictive value; NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index.

###### 

Associations between Noninvasive Fibrosis Markers and CACS \>100 Stratified by Age

  Variable                OR (95% CI)             p-value
  ----------------------- ----------------------- ---------
  Age \<55 yr                                     
   NAFLD fibrosis score   3.521 (0.979--12.663)   0.054
   FIB-4                  2.141 (0.761--6.024)    0.149
   Forn's index           1.364 (0.486--3.832)    0.556
   APRI                   2.518 (0.789--8.037)    0.119
  Age ≥55 yr                                      
   NAFLD fibrosis score   7.929 (1.053--59.686)   0.044
   FIB-4                  4.645 (1.074--20.083)   0.04
   Forn's index           3.279 (0.963--11.164)   0.057
   APRI                   2.794 (1.256--6.216)    0.012

CACS, coronary artery calcium score; OR, odds ratio; CI, confidence interval; NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index.
